Stichworte
Behandlungsbedürftigkeit, Begutachtung ×
Leukämie ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

76 Suchergebnisse.

Sortieren (Relevanz) ▾

Eligibility Refractory TdT-Positive Leukemia NCT00709215

- 25.09.18 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00709215

Eligibility Refractory Leukemia NCT00880269

- 25.09.18 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT00880269

Eligibility Leukemia NCT01050764

- 23.05.18 - 1 Formular, 1 Itemgruppe, 25 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Haploidentical Allogeneic Transplant w/Post Transplant Infusion of Regulatory T-cells (BMT Protocol 204); ODM derived from: https://clinicaltrials.gov/show/NCT01050764

Eligibility Leukemia NCT01038635

- 22.05.18 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01038635

Eligibility Leukemia NCT00990249

- 22.05.18 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT00990249

Eligibility Leukemia NCT00897182

- 19.05.18 - 1 Formular, 1 Itemgruppe, 11 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00897182

Eligibility Leukemia NCT00897078

- 19.05.18 - 1 Formular, 2 Itemgruppen, 22 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of Metabolic Syndrome in Young Patients Who Are Acute Lymphoblastic Leukemia Survivors and Their Healthy Siblings; ODM derived from: https://clinicaltrials.gov/show/NCT00897078

Eligibility Leukemia NCT00891137

- 19.05.18 - 1 Formular, 1 Itemgruppe, 18 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT00891137

Eligibility Leukemia NCT00882076

- 18.05.18 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias; ODM derived from: https://clinicaltrials.gov/show/NCT00882076

Eligibility Leukemia NCT00860522

- 18.05.18 - 1 Formular, 2 Itemgruppen, 20 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00860522

Eligibility Leukemia NCT00844441

- 18.05.18 - 1 Formular, 1 Itemgruppe, 21 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00844441

Eligibility Leukemia NCT00800566

- 18.05.18 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00800566